Objectives

Pre-clinical trial validated ETEC and Shigella assays qualified for clinical phase testing
Pre-clinical test results qualify ETEC and Shigella real-time PCR assays as lead candidates for transition to clinical phase testing. Diagnostic sensitivity results were ≥ 96% to ≤ 100% in testing conducted under laboratory and field conditions. Current commercially available molecular-based diagnostic assay sensitivity is ≥ 95% to ≤ 98% representing the standard that must be met or exceeded to qualify as a candidate for FDA clearance. Results are provided in final reports.
In addition to test activities, Enterotoxigenic Escherichia coli Detection Kit and Shigella Detection Kit pre-IDE documents were prepared to serve as a point of departure for discussion with the FDA Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) on guidance and clarification of specific testing requirements for eventual clearance.
Report describing ABI 7900 and RAPID/JBAIDS pre-clinical test results
Testing was successful (See Results section). Analytical test results are shown in Appendix C.
Completed PEC, NEC, IPC and comparator test evaluations
Controls and comparator test are established (See Results section).
Quarterly Progress and Expense Analyses Reports and Final report submitted to the Defense Technical Information Center (DTIC)
Copies of reports can be obtained through Project Manager, 59
th MDW/ST.
Graduate Medical Education (GME) research project completed
During the conduct of RDT&E activities a formal GME training program was established by the investigators. The program provides for scholarly and challenging research opportunities in a real-world environment. Under this project, an Air Force resident physician completed research which directly resulted in advancing Force Health Protection diarrheal disease diagnostic technologies toward clearance. Two separate research projects were completed, abstracts prepared, and posters presented at a medical symposium. The resident successfully completed WHAMC Pathology Department Research Elective 144. These projects are described in the Results section. Project activities are provided in Appendix A and course description and requirements are provided in Appendix B.
Summary
The objectives of this study were accomplished. Real-time diarrheal disease causative agent detection capability was advanced through pre-clinical test phase. The GME component of this study was successfully completed. 
Products Completed
Point-of-care high throughput system (HTS) and deployable real-time PCR detection capability for diagnosis of etiologic agents of diarrheal disease were accomplished. Pre-clinical test phase demonstrated that ETEC LT, STIa, STIb, and Shigella spp. assays exceeded the objective diagnostic sensitivity. The assays proved specific in testing using a broad panel of clinically significant and genotypically similar organisms.
Purpose
The work completed under this project is follow-on to joint projects completed through previous AF/SGR AFMSA/SG5I funded efforts undertaken by the 59 th MDW and Department of Enteric Diseases, AFRIMS. Success in these collaborative efforts has positioned military significant disease agent diagnostics for FDA clearance. Under this project, advanced to clinical test phase are real-time PCR assays for enterotoxigenic Escherichia coli (ETEC) toxin genes, Heat Stable Ia (STIa), Heat Stable Ib (STIb), and Heat Labile (LT) and Shigella enteroinvasive E. coli (EIEC) spp. The associated training objective provided a scholarly and challenging opportunity in GME.
Pre-clinical testing of previously established ETEC and Shigella PCR assays was conducted using two functionally distinct FDA cleared real-time PCR instruments. The first is state of the art laboratory equipment, the Fast Real-Time PCR System (Applied Biosystems, Inc. 7900). This HTS is capable of rapidly screening large numbers of samples, hundreds to thousands, per day. Rapid identification of bacterial disease agents by HTS screening of clinical and environmental samples provides for efficacious treatment and disease prevention. The second PCR instrument is the portable, field-deployable DoD Joint Biological Agent Identification and Diagnostic System (JBAIDS). Disease outbreaks often occur in developing regions and often coincide with natural or man-made disasters. In situations of underdeveloped or failing health care infrastructure, the JBAIDS provides a valuable aid in disease surveillance and diagnosis. The JBAIDS is deployed in hours and capable of operating independently of conventional laboratory infrastructure.
Assay testing was conducted in compliance with Good Laboratory Practice (GLP) standards established by the FDA specifically for in vitro diagnostic device (IVD) clearance. Pre-clinical test results reported here will be used to seek funding for clinical phase testing as well as biosurveillance kit development.
Problem
The ability of military medical personnel to accurately diagnose and recognize diarrheal disease threats in an operational environment is a high priority. The rapid identification of an infectious agent will allow for prompt, appropriate treatment, thereby minimizing morbidity and mortality. Additionally, knowledge about a specific infectious disease threat will allow for the implementation of appropriate prevention and control measures to protect the fighting force.
Results of Pre-clinical Performance
Diagnostic Sensitivity -pre-clinical phase testing showed that JBAIDS TaqMan assays for enterotoxigenic Escherichia coli (ETEC) toxin genes, Heat Stable Ia (STIa), Heat Stable Ib (STIb), and Heat Labile (LT) and Shigella enteroinvasive E. coli (EIEC) spp. exceeded the objective diagnostic sensitivity, ≥ 95% to ≤ 98% [ Table 1 ]. Specificity test results reported here, and in previous testing, showed that the assays are specific (Appendix C). This study was conducted to determine the performance of the assays for relevant specimen types claimed in future labeling. The study protocol provides patient sample inclusion and exclusion criteria, type and number of specimens, directions for use, and statistical analysis information will be used for potential premarket submission. The specimen types (strains) and total number of samples were based on diarrheal disease epidemiological data. The objective number of samples was a minimum of 30 confirmed positive using the reference method. Preclinical studies were conducted at a single facility utilizing a single laboratory. Testing was conducted by experienced and trained personnel at the Department of Enteric Diseases, AFRIMS. This laboratory is the only DoD facility currently conducting diarrheal disease agent clearance activities. The study population included archived nucleic acid extracts from individuals who presented with diarrheal disease. Results were compared using the established reference method (culture). In addition to culture sequencing of amplicon was used for confirmation testing.
Interference Study
Stool presents a relatively complex challenge in sample preparation. Stool harbors an array of PCR interfering substances that must be removed during the nucleic acid extraction process to help assure an efficacious level of diagnostic sensitivity.
A preliminary interference study was successfully completed using clinically relevant conditions. The interferent used was human blood which represents the primary PCR inhibitory substance encountered in stool specimens. The interferent was tested at the potentially "the worst case" concentration (10% w/w) using two strains of organism (ETEC LT and Shigella) to assess the potentially inhibitory effects. Interference testing was conducted at LoD and 1000X LoD concentrations of organism to assess inhibitory effects as well as to assess potential for crosscontamination.
There was no significant difference in ETEC LT assay Ct values for stool prepared with spikedblood and non-spiked samples (below). Testing conducted using the Shigella assay also did not indicate interference. Throughout testing there was no indication of cross-contamination. Study design and JBAIDS screen shots are shown below. 
Positive Extraction Control (PEC), Negative Extraction Control (NEC), Internal Positive Control (IPC) and Comparator Test
Negative Controls
No template control (NTC) -The NTC reaction contains buffer and all of the assay components except nucleic acid. These controls ruled out contamination with target nucleic acid or increased background in the amplification reaction. No template control reactions were manufactured by Idaho Technology, Inc (now BioFire Diagnostics), Salt Lake City, Utah.
Negative sample control
The negative sample control contained non-target nucleic acid. When used to evaluate extraction procedures it contained whole organism to reveal non-specific priming or detection and to indicate that signals were obtained in the absence of target sequences. Negative sample control materials included:
 Patient specimen from a infected individual  Samples containing a non-target organism
Positive Controls
Positive control for complete assay -The positive control contained well characterized target nucleic acid to control the entire assay process, including DNA extraction, amplification, and detection. It was designed to mimic a patient specimen and to be run as a separate assay, concurrently with patient specimens at a statistically significant frequency. As stated in the proposal, the development and validation of a positive control will require additional funding through follow-on proposal.
Positive control for amplification/detection (PTC) -The PTC for amplification/detection contained purified well characterized target nucleic acid. The PTC was designed to report fluorescence at or near the LoD. The PTC controlled the integrity of the patient sample and the reaction components when negative results were obtained and to indicate that the target is detected if present in the sample. The PTC was manufactured by Idaho Technology, Inc (now BioFire Diagnostics), Salt Lake City, Utah.
Internal Positive Control -Various candidate PCR internal positive controls (IPC) were evaluated for down-selection and testing. The IPC is a non-target nucleic acid sequence that is co-extracted and co-amplified with the target nucleic acid. It will control the integrity of the reagents (polymerase, primers, etc.), PCR instrument function, and the presence of inhibitors in the samples. The human housekeeping gene β-actin was selected for IPC development. As stated in the proposal, the IPC will require additional funding through follow-on proposal.
Comparator Test -gold standard methodology was used as the comparator test (culture) with confirmation testing of amplicon by DNA sequencing. In addition, ETEC LT, ETEC STIa, and ETEC STIb diagnostic sensitivity test results were compared to a DIG multiplex reaction for the ETEC agents. Shigella diagnostic sensitivity results were compared to serological analyses.
Assay Storage Conditions -A thermal stability study demonstrated that the assays generate equivalent results at several time points throughout the duration of the recommended storage and at both ends of the recommended temperature range. Thermal stability studies were conducted under the GME project. See Results section "Graduate Medical Education Project".
ABI 7900 Transfer
Transfer of JBAIDS formatted assays to the ABI 7900 was successfully completed. Study design is shown in Table 2 . Optimized assay formulations and reaction conditions are shown in Table 3 . Average Ct Values of Standard Curves from triplicate of 4-folds serial dilutions of ETEC, Shigella, and Cryptosporidium assays are shown in Table 4 . Standard curves are shown in Figures 1 -5 . Limit of detection estimation derived from standard curve are shown in Table 5 . These data include results from both 'JBAIDS ETEC/Shigella' and 'JBAIDS Cryptospordium' projects.
Standard cuve for estimate LOD Materials and Methods:
1. Isolated colonies for each pathogens were selected and picked from sub culture agar plate (1 loopful) 2. The colonies were suspended in normal saline separately. 3. Suspended colonies were measured at 625 nm and adjusted to 0.5 McFarland (OD 625nm 0.088 -0.133). 4. Nucleic acids extraction was performed using boiling method. "During this time of economic restriction, there is an increased pressure on the scientific community to cut costs and stretch research dollars. We performed assay stability testing on the Shigella ipaH PCR reaction assay produced by Idaho Technologies (Salt Lake City, Utah). The original test kits were produced using good manufacturing practices and field tested in Nepal in the spring of 2009. Afterward, these assays were stored at -25°C. In September 2011, we started testing with the same probe/primer designed test assays on the same instrument with similar samples and identical PCR protocol. Our results showed an average critical point (Cp) value of 27.41 (SD 0.48, n=5) for the Shigella positive template control (PTC). The data obtained in Nepal had an average Cp of 27.24 (SD 0.87, n=3). These averages are within a greater than 95% confidence interval. Secondarily, we demonstrated no loss in limit of detection (LOD). Our results indicated detection to the level of 1.5X10 3 CFU/ml. Reproducibility with 12 samples at the LOD was verified (mean Cp 38.4 with SD 0.88). The results are comparable to the results found in Nepal two years ago. Furthermore, the correlation coefficient of the standard extract was -0.98 to -1.00. In conclusion, these findings validate the stability of the freeze dried primer/probe Taqman reagent mix and could potentially be used to not only facilitate logistics for future research/clinical testing but also decrease costs. Furthermore, in pre-positioning the inventory of these critical detection assays, public health emergency preparedness is enhanced." "We describe here a rapid, field deployable stool nucleic acid extraction process which shows promise for field diagnostic use. A highly modified, streamlined protocol was adapted from a preformatted commercial kit (QIAamp Viral RNA Mini Kit, Qiagen, Valencia, CA). The modified protocol eliminated the need for cold storage or hot water bath. All steps were carried out at ambient temperature using readily available agents. The procedure was performed in approximately one hour for the extraction of ten samples. The extracts were then run on a fielddurable, real-time PCR thermocycler the "Ruggedized" Advanced Pathogen Identification Device (RAPID). The limit of detection was 1.5X10 6 CFU/ml on Shigella flexneri extract spiked negative stool. This protocol was further tested using Shigella sonnei cultured organisms and Shigella positive stool from three different patients. All organisms tested were DNA sequenced or identified via culture methods. There was no cross-reactivity between Shigella sonnei and other enteric pathogens including E. coli (ETEC) LT, ETEC-ST1a, or ETEC-ST1b. The results were 100% sensitive and 100% specific. These test results demonstrate a rapid and reliable method with potential for field diagnostics in austere environments with further field testing to be completed."
Shigella Stool Extraction with Taqman Detection
Rebekah Piegols MD, Joseph Pelletier MD, James M cAvin lntrodtu:tiol~ For at least the last tV\0 decades, DNA extraction has been performed on stool spedmens, both animal and human. In the deployed ordisaster (publichealth torus) setting, there are limited logistic capabilitiesWth pa'ytoad limitations. Expanding or extendingthe use of available prei)ackaged m&terias is set at a premium, especiallyWth the current economyand budget cuts. We propose that the QIAmp VIral RNAmini k~ (Qiagen, Valenda, CA) is a viable option to other DNAstool extraction kits. Here V\e describe a rapid, 1ield deployable stool nucleic acid extraction process V\hich shows promise for 1ield
Mort erial and Methods: Ahighlymodified, streamlined protocol \1\eS adapted from a preformatted commercial kit (Qift.amp Viral RNAMini Kit, Qiagen, Valenda, CA). The modified protocol eliminatedthe need tor cold storage or hot V\6\er bath . .AJI steps V~.ere carried out at ambient temperature using readilyavailable agents. The procedure V\EIIS perfonned in approximatelyone hour for the extraction often samples. The extracts 'Y\ere then run on a field-durable, real-time PCR thermocyderthe "Ruggedized" .Advanced Pathogen Identification Device (RAPID). ;.-··--
Concl usi on/Di scussi en: ~hough this was a limited study, these test results demonstme a rapid and reliable method with potential for 1\eld diagnostics in austere en\jjronments with funher 1\eld testing to be completed. The results demonstr.ned similar detection limits as those found when extracting the DNA from cultured organisms. Detection of Shigella 11exneri from DNA extracted from cultures was found to be 1.5 x 10" CFUhnl (by correspondence). Elctractingthe DNAdirectlyfrom the patient specimens will save time, energy. manpower and money leading to a more efficient diagnostic procedure. This will not only add to cost sa\jjngs in medical diagnosis but also decrease the morbidity and potential monalityofpatients suffering from infections with these pathogens through a quicker, more speci1\ctreatment plan. 
Conclusion
Work conducted under this study advanced real-time diarrheal disease causative agent diagnostic assays through pre-clinical test phase. Results reported qualify the assays as lead candidates for clinical phase testing. A GME training program was established which provided for scholarly and challenging research opportunity in a real-world environment.
Appendix A Graduate Medical Education
The investigators conducted the following GME activities: preparation of course materials, development of a research project, preparation of a Research Plan and Training Schedule, integration (and de-integration) of the GME laboratory, reagent and sample preparation, coordination and execution of GME research activities, mentored the resident in proposal writing and results reporting, maintained daily log of resident activities and progress, assured the safety and wellbeing if GME participants. The GME Research Plan and Training Schedule and detailed description of activities are provided below.
Course Summary and Schedule
Research Elective 144
Goals and Objectives: to gain a better understanding of the scientific method and the acquisition of new knowledge through a mentored research experience. The resident will demonstrate ACGME competencies in medical knowledge, practice-based learning and improvement, interpersonal and communication skills, and professionalism.
General objectives are to:
1. Acquaint the resident with a particular area of medical-related research.
2. Teach the resident appropriate research techniques and research design. To learn to access, critique, and assimilate the current medical literature pertaining to the research topic (Practice-Based Learning).
To gain an understanding of the scientific method by learning to write an IRB approved research protocol (Practice-Based Learning).
To learn and understand the purpose of informed consent and the regulatory approval process in the setting of research ethics by completing the HIPPA compliance training and obtaining IRB approval for the proposed research project (Professionalism and Systems-Based Practice).
To perform the research and develop the necessary skills required to do this such as laboratory techniques and computer skills (Practice-Based Learning).
To learn and apply the appropriate data analysis and basic biostatistics needed for the project (PracticeBased Learning).
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Outcomes assessment: Subjective -A standard competency-based trainee evaluation will be completed at the end of the rotation by the faculty research mentor.
Evaluation
All projects are graded by the Program Director or Associate Program Director using the standard score sheet on the SAUSHEC web site (see appendices A and B). A minimum score of 60 is required to graduate. It is highly recommended that the resident strive for first authorship on a publication in any of the categories listed in the appendix.
Course objectives: the objective of this course is to meet Resident Program requirements in the conduct and completion of a research rotation.
The resident will demonstrate knowledge and proficiency in:
1. IRB protocol and associated documentation preparation and progress reporting.
2. Proposal preparation, funding application preparation and submission, and reporting process. 5. The preparation of a scholarly abstract and submission to a scientific meeting or symposium.
6. Presentation of results at a scientific symposium, conference, or meeting.
The student will meet or exceed the requirements for completion of Research Elective 144. At the conclusion of the course the student will have prepared a research pre-proposal and statement of work that is suitable for submission for funding. The student will be prepared to submit the associated IRB documentation. The student will have demonstrated the ability to independently conduct and complete a research project and report the results.
Week 1 29 August, 2011 Course Preparation and Travel to Field Site Monday 29
Literature review and conduct literature search (suggested key words; diarrheal disease, ETEC, Shigella, Cryptosporidia diagnostics, real-time PCR, RAPID/JBAIDS).
Send itinerary and contact information to PI.
Tuesday 30
Review and organize travel file (travel documents, readiness file, GME Training Plan, ETEC/Shigella and Cryptosporidium proposals, and research articles).
Wednesday 31
Pack and prepare for departure. Confirm link-up time/location with travel companions and confirm with PI contact information, arrival time and pick-up location. 
GME Goals and Objectives
The student will meet or exceed the requirements for completion of Research Elective 144. At the conclusion of the course the student will have prepared a research pre-proposal and statement of work that is suitable for submission for funding. The student will be prepared to submit the associated IRB documentation. The student will have demonstrated the ability to independently conduct and complete a research project and report the results. 
1300-1700
Organize and archive research results and symposium planning.
Tuesday 27
-1700
Pack and prepare for departure (hotel check-out). To learn to access, critique, and assimilate the current medical literature pertaining to the research topic (Practice-Based Learning).
Research Elective 145
To demonstrate communication skills by presenting research results to program directors and fellow residents and/or presenting results at a national meeting and/or writing a paper for publication in medical journals (Interpersonal and Communication Skills).
Resident Duties and Responsibilities:
To receive elective credit for research, the resident must complete the following minimum requirements:
. Identify a faculty research mentor and proposed project.
. Submit a brief (1-2 page) summary of a proposed research project and a research plan with study design and timeline (which may consist of the IRB protocol) to be approved by Residency Program Director or Associate Director and the research mentor.
. Complete the Collaborative Institutional Training Initiative (CITI training) on line research training module.
. Obtain regulatory approval for the project, as appropriate. In most cases this will include writing and submitting a protocol to the IRB.
. Present findings to fellow residents and program directors or at a national meeting in the form of a poster or as a publication in a medical journal.
. Submit a final product to the program directors. This may be an abstract, a poster presentation, the draft of a paper, or a publication.
. Attend all regularly-scheduled academic conferences, other military duties, and conferences as assigned.
. Obtain prior approval for time spent away from the primary training sites (BAMC and WHMC).
Outcomes assessment: Subjective -A standard competency-based trainee evaluation will be completed at the end of the rotation by the faculty research mentor. 
Appendix C
Through earlier AF/SGR funded projects we developed highly sensitive and specific, dualfluorogenic, hydrolysis probe (TaqMan), RAPID/JBAIDS PCR assays for the detection of enterotoxigenic Escherichia coli (ETEC) toxin genes, Heat Stable Ia (STIa), Heat Stable Ib (STIb), and Heat Labile (LT) and Shigella/enteroinvasive E. coli (EIEC) species. Our results indicated that the ETEC and Shigella assays are more sensitive than the current gold standard methodology.
The ETEC assay LOD for STIa, STIb, and LT were established at ≤ 1000 fg (≤ 100 genomic equivalent) for each assay (Tables C1 and C2 ). Typical RAPID run results are shown in Figure  C1 . Assay in vitro sensitivity was 100% and specificity 100% concordant with well characterized E. coli reference strains, genetic near neighbors, and broad cross-reactivity panel to include human DNA (Tables C3 and C4 ). In field-based, blind testing using a panel of fresh stool samples (n=118) STIa, STIb and LT assay sensitivity test results were all 100% concordant and specificity test results were STIa (92.4%), STIb (92.6%), and LT (79.6%) concordant with DNA sequencing results (14). Based on the standard curves, the 4 th dilution of all known ETEC strains (equivalent to 1.5×10 4 cell/mL) was selected to represent the assays LOD. Those cell concentrations were used to perform downstream reproducibility experiments. Note: R 2 of unity is based on the robustness of linearity achieved by the PCR. For optimized reactions that have met validation criteria, a "Best Fit" algorithm is utilized to automatically calculate correlation at an assumed value of unity. Assay sensitivity and specificity are assumed to be 100% for the calculation of infection rate (16, 17). The Shigella/EIEC-ipaH assay limit of detection (LOD) was established at < 100 fg (< 10 genomic equivalent) [ Tables C5, C6 and Figure C2 ,C3]. Assay in vitro sensitivity was 100% and specificity 100% concordant with well characterized Shigella reference strains, near genetic near neighbors, and broad cross-reactivity panel to include human DNA (Tables C4 and C7 Based on linearity evaluation standard curves, the 5 th dilution of known Shigella strain (equivalent to 1.5×10 3 cell/mL) was selected to represent the assays LOD. Those cell concentrations were used to perform downstream reproducibility experiments. Note: R 2 of unity is based on the robustness of linearity achieved by the PCR. For optimized reactions that have met validation criteria, a "Best Fit" algorithm is utilized to automatically calculate correlation at an assumed value of unity. Assay sensitivity and specificity are assumed to be 100% for the calculation of infection rates. Figure C3 . Assay reproducibility of Shigella/EIEC-ipaH assay on RAPID platform 
